MAIAMaia BiotechnologySigning up patients
A Phase III Study With THIO + Cemiplimab vs Chemotherapy as 3rd Line Treatment in Advanced/Metastatic NSCLC
Carcinoma, Non-Small -Cell Lung
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 3
- Patients
- 300 (planned)
- Started
- Dec 8, 2025
- Main results expected
- Jul 31, 2027
- Fully finished
- Dec 31, 2027
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Overall Survival
Measured over: Within 2 Years
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT06908304 · record last updated 2026-01-12 · checked 2026-11-09 15:47 UTC